Showing results (171-180 of 217) with videos related to
Sort By:
Pageof 22
JAMA Oncology|September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical TrialGeorge W Sledge, Masakazu Toi, Patrick Neven, et al.Cancer Research|April 15, 2010
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapyGiulia Grisendi, Rita Bussolari, Luigi Cafarelli, et al.Future Oncology (London, England)|May 14, 2021
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further linesAlessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, et al.Plos One|March 21, 2019
Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related eventsSalvatore Grisanti, Susanna Bianchi, Laura D Locati, et al.The Oncologist|April 16, 2022
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving NivolumabGiulia Pasello, Martina Lorenzi, Lorenzo Calvetti, et al.The New England Journal of Medicine|May 16, 2019
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast CancerFabrice André, Eva Ciruelos, Gabor Rubovszky, et al.Journal of Personalized Medicine|January 21, 2022
Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in EuropeDenis Horgan, Giuseppe Curigliano, Olaf Rieß, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2021
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1Eva Maria Ciruelos, Hope S Rugo, Ingrid A Mayer, et al.Therapeutic Advances in Medical Oncology|March 20, 2023
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapyGiovanna Garufi, Luisa Carbognin, Isabella Sperduti, et al.Cancer Treatment Reviews|August 28, 2023
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spreadCarmen Criscitiello, Chiara Corti, Michelino De Laurentiis, et al.Pageof 22